Vaginal progesterone to reduce the rate of preterm birth and neonatal morbidity: A solution at last

Women's Health

Volumn 7, Issue 5, 2011, Pages 501-504

  Romero, Roberto ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

cost effectiveness; parturition; prematurity; preterm labor; preterm labor syndrome; progestins; progestogens; short cervix; ultrasound; uterine cervix

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; PLACEBO; PROGESTERONE;

BIRTH RATE; CORPUS LUTEUM; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GESTATIONAL AGE; HEALTH CARE COST; HUMAN; INTRAUTERINE GROWTH RETARDATION; NEWBORN MORBIDITY; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; RESPIRATORY DISTRESS SYNDROME; REVIEW; TRANSVAGINAL ECHOGRAPHY; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX;

ADMINISTRATION, INTRAVAGINAL; CERVIX UTERI; COST-BENEFIT ANALYSIS; FEMALE; GELS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; PROGESTERONE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; ULTRASONOGRAPHY, PRENATAL; VAGINA;

EID: 80052453773     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.60     Document Type: Review

References (24)

1. Beck S, Wojdyla D, Say L et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull. World Health Organ. 88(1), 31-38 (2010).
2. Gotsch F, Romero R, Kusanovic JP et al. The fetal inflammatory response syndrome. Clin. Obstet. Gynecol. 50(3), 652-683 (2007). (Pubitemid 47357241)
3. Romero R. Prenatal medicine: the child is the father of the man. 1996 J. Matern. Fetal Neonatal Med. 22(8), 636-639 (2009).
4. Di Renzo GC. The great obstetrical syndromes. J. Matern. Fetal Neonatal Med. 22(8), 633-635 (2009).
5. Romero R. Prevention of spontaneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment. Ultrasound Obstet. Gynecol. 30(5), 675-686 (2007). (Pubitemid 47612688)
6. Hassan SS, Romero R, Berry SM et al. Patients with an ultrasonographic cervical length (Pubitemid 30437417)
7. Heath VC, Southall TR, Souka AP et al. Cervical length at 23 weeks of gestation: prediction of spontaneous preterm delivery. Ultrasound Obstet. Gynecol. 12(5), 312-317 (1998). (Pubitemid 28517634)
8. Iams JD, Goldenberg RL, Meis PJ et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N. Engl. J. Med. 334(9), 567-572 (1996). (Pubitemid 26066130)
9. Grimes-Dennis J, Berghella V. Cervical length and prediction of preterm delivery. Curr. Opin. Obstet. Gynecol. 19(2), 191-195 (2007). (Pubitemid 46412109)
10. Fonseca EB, Celik E, Parra M et al. Progesterone and the risk of preterm birth among women with a short cervix. N. Engl. J. Med. 357(5), 462-469 (2007). (Pubitemid 47204875)
11. DeFranco EA, O'Brien JM, Adair CD et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebocontrolled trial. Ultrasound Obstet. Gynecol. 30(5), 697-705 (2007). (Pubitemid 47612690)
12. O'Brien JM, Defranco EA, Adair CD et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebocontrolled trial. Ultrasound Obstet. Gynecol. 34(6), 653-659 (2009).
13. Hassan SS, Romero R, Vidyadhari D et al.Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet. Gynecol. 38(1), 18-31 (2011).
14. Rode L, Klein K, Nicolaides K et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo-controlled trial on the effect of vaginal micronised progesterone. Ultrasound Obstet. Gynecol. doi: 101002/uog.9093 (2011) (Epub ahead of print).
15. Campbell S. Universal cervical-length screening and vaginal progesterone prevents early preterm births, reduces neonatal morbidity and is cost saving: doing nothing is no longer an option. Ultrasound Obstet. Gynecol. 38(1), 1-9 (2011).
16. Werner EF, Han CS, Pettker CM et al. Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis. Ultrasound Obstet. Gynecol. 38(1), 32-37 (2011).
17. Cahill AG, Odibo AO, Caughey AB et al. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am. J. Obstet. Gynecol. 202(6), 548e1-548e8 (2010).
18. Norman JE, Mackenzie F, Owen P et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebocontrolled study and metanalysis. Lancet 373(9680), 2034-2040 (2009).
19. Rouse DJ, Caritis SN, Peaceman AM et al. A trial of 17 a-hydroxyprogesterone caproate to prevent prematurity in twins. N. Engl. J. Med. 357(5), 454-461 (2007). (Pubitemid 47204874)
20. Combs CA, Garite T, Maurel K et al. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am. J. Obstet. Gynecol. 204(3), 221 e1-221e8 (2011).
21. Durnwald CP, Momirova V, Rouse DJ et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17 hydroxyprogesterone caproate. J. Matern. Fetal Neonatal Med. 23(12), 1360-1364 (2010).
22. Klein K, Rode L, Nicolaides K et al. Vaginal micronized progesterone and the risk of preterm delivery in high-risk twin pregnancies - secondary analysis of a placebo-controlled randomized trial and metanalysis. Ultrasound Obstet. Gynecol. doi: 101002/uog.9092 (2011) (Epub ahead of print).
23. Owen J, Hankins G, Iams JD et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am. J. Obstet. Gynecol. 201(4), 375e1-375e8 (2009).
24. Kusanovic JP, Romero R, Chaiworapongsa T et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and antingiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J. Matern. Fetal Neonatal Med. 22(11), 1021-1038 (2009).